The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.
 
Edoardo Francini
Travel, Accommodations, Expenses - Janssen-Cilag
 
Francesco Montagnani
No Relationships to Disclose
 
Nuzzo Pier Vitale
No Relationships to Disclose
 
Nimira S. Alimohamed
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen; Merck; Pfizer; Sanofi
 
Irene Moreno Candilejo
No Relationships to Disclose
 
Pietro Rosellini
No Relationships to Disclose
 
Miguel Gonzalez-Velez
No Relationships to Disclose
 
Jaime Rubio
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose
 
Grace Shaw
No Relationships to Disclose
 
Francesca Crivelli
No Relationships to Disclose
 
Roberto Petrioli
No Relationships to Disclose
 
Carmelo Bengala
No Relationships to Disclose
 
Guido Francini
Research Funding - Roche Pharma AG
Other Relationship - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Ipsen; Janssen; Lilly; Merck; MSD Oncology; Novartis; Pfizer; Sanofi
 
Jesus Garcia Foncillas
Consulting or Advisory Role - Merck
 
Alan Haruo Bryce
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Lauren Christine Harshman
Consulting or Advisory Role - Bayer; Corvus Pharmaceuticals; Exelixis; Genentech; Jounce Therapeutics; Merck; Novartis; Pfizer; Theragene
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Endocyte (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bayer
 
Richard Lee-Ying
Consulting or Advisory Role - Celgene; Ipsen; Pfizer; Sanofi
Speakers' Bureau - Celgene; Janssen
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)